COVID-19 panel recommends DCGI to permit SII to conduct human trials of Oxford vaccine candidate Read more
SLAs to issue manufacture/sale licenses for AYUSH formulations only after approval from AYUSH Ministry Read more
Health ministry decides against including Itolizumab in clinical management protocols for COVID-19 Read more
DCGI queries pharma company on its claim of FabiFlu use for COVID-19 patients with comorbidities Read more